Regarding melanoma treatment, three combinations of BRAF and MEK inhibitors have received approval from the FDA: vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib. The gene discussed is MAP2K7; the disease is melanoma.